Buy Suven Pharmaceuticals; target of Rs 650: ICICI Direct
ICICI Direct is bullish on Suven Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 650 in its research report dated August 16, 2021.
August 19, 2021 / 01:31 PM IST
ICICI Direct's research report on Suven Pharmaceuticals
Suven Pharma is a CDMO that supports global life sciences industry & fine chemical majors in their NCE development endeavours. Its services include custom synthesis, process R&D, scale-up & contract manufacturing. Business comprises three segments – CDMO (development projects and commercial supplies), specialty chemicals and contract technical service CDMO vertical contributes more than 62% of its topline. Owing to its CDMO competence, it has developed & supplies intermediates for two specialty chemical products (agrochemical) to large global conglomerates
We retain our BUY rating on this stock We value Suven at Rs 650 with 32x P/E on FY23E EPS
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.